CHU, JENNIFER HSING-CHUNG,SHAH, GAUTAM,PHADKE, AVINASH
申请号：
CA2905423
公开号：
CA2905423A1
申请日:
2014.03.13
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.
